Fig. 5
Therapeutic efficacy of image-guided INC280-PFCE NPs in NSCLC liver metastasis. A Schematic showing NSCLC liver metastasis model imaging and the treatment schedule. The mice were divided into 4 groups, Control, PFCE NPs, INC280 and INC280-PFCE NPs (n = 13 per group). PFCE NPs group: a single 100 µL of PFCE NPs was administered by IV injection. INC280 group: free INC280 was orally given at 3 mg/kg every day and total drug doses were 840 µg in a 14-day treatment cycle. INC280-PFCE NPs group: a single dose 100 µL of INC280-PFCE NPs group (with an INC280 content of 179.5 µg in total per treatment cycle of 14 days) was administered by IV injection. B In vivo 19F-MRI after IV injection of INC280-PFCE NPs. C Quantification of the accumulation of INC280-PFCE NPs in tumors (n = 3). D H&E staining of NSCLC liver metastasis displaying two metastatic lesions circled with white dotted lines. (scale bar = 500 µm) E Representative T2-weighted MRI of mice at different times. F Quantification of the volume of metastases from the T2-weighted MR images of mice (n = 5). G Quantification of the volumes of the livers that were occupied by metastases (n = 5). H The liver/body ratios, a parameter of tumor burden, among the four groups were compared on day 14 posttreatment (n = 5). I Quantitative analysis of the metastatic nodes number in the T2-weighted MR images from mice receiving different treatments (n = 5). J Gross appearance of NSCLC liver metastases following different therapies. The scale bar is 1 cm. K Survival curves of NSCLC liver metastasis model mice (n = 8). L At the end of therapy, H&E staining of the livers. Scale bar is 100 µm. The results are presented as mean ± standard deviation. **P < 0.01, ***P < 0.001, and ****P < 0.0001